Which cancers is Tislelizumab suitable for?

Tislelizumab is a PD-1 monoclonal antibody independently developed by BeiGene. As an immune checkpoint inhibitor, it activates the immune killing effect of T cells on tumor cells by blocking the binding of the PD-1 receptor and its ligands PD-L1/PD-L2. It has been approved for the treatment of multiple cancer types in China and has gradually become an important immunotherapy option for a variety of intermediate and advanced malignant tumors.

Tislelizumab is approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), including patients who have progressed on first-line combination chemotherapy and second-line single-agent therapy. Studies have shown that tislelizumab has a good objective response rate (ORR) and long-term survival benefit in NSCLC patients with high PD-L1 expression, and is one of the more mature immunotherapy options at present.

In addition to lung cancer, tislelizumab is also approved for the treatment of previously treated locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), and recurrent/metastatic nasopharyngeal carcinoma (NPC). Especially in Asia's most common cancer types, such as liver cancer and nasopharyngeal cancer, tislelizumab has shown a high disease control rate, broadening its clinical application scope.
Tislelizumab is mainly suitable for patients with intermediate and advanced cancer, especially those who are ineffective or resistant to traditional chemotherapy or targeted therapy. Patients need to undergo PD-L1 expression detection, tumor burden assessment, and comprehensive physical condition judgment before taking medication. Standard use under the guidance of a doctor will help achieve better treatment effects and quality of life. At the same time, you need to be alert to immune-related adverse reactions, such as rash, hepatitis or pneumonia.
Reference: https://www.drugs.com/